These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 10762129

  • 1. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model.
    Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW.
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S22-32; discussion S32-4. PubMed ID: 10762129
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dyskinesias and the subthalamic nucleus.
    Benabid AL, Benazzouz A, Limousin P, Koudsie A, Krack P, Piallat B, Pollak P.
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S189-92. PubMed ID: 10762147
    [Abstract] [Full Text] [Related]

  • 5. Clinical physiology of dopa dyskinesia.
    Hallett M.
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S147-50; discussion S150-3. PubMed ID: 10762142
    [Abstract] [Full Text] [Related]

  • 6. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E, Brotchie JM, Gross CE.
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Surgery for levodopa-induced dyskinesias.
    Lang AE.
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S193-9; discussion S199-202. PubMed ID: 10762148
    [Abstract] [Full Text] [Related]

  • 9. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV, Hauser RA.
    Eur Neurol; 2008 Apr; 60(2):57-66. PubMed ID: 18480609
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.
    Cheshire PA, Williams DR.
    J Clin Neurosci; 2012 Mar; 19(3):343-8. PubMed ID: 22249009
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH, Chuang R, Brotchie JM.
    Prog Brain Res; 2008 Mar; 172():479-94. PubMed ID: 18772047
    [Abstract] [Full Text] [Related]

  • 15. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R, Schulzer M, Mak E, Calne DB, Stoessl AJ.
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.